Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$9.77 - $21.47 $219,883 - $483,203
22,506 Added 38.35%
81,185 $1.2 Million
Q4 2023

Feb 09, 2024

SELL
$4.48 - $10.11 $483,884 - $1.09 Million
-108,010 Reduced 64.8%
58,679 $564,000
Q3 2023

Nov 13, 2023

SELL
$4.48 - $6.19 $37,439 - $51,729
-8,357 Reduced 4.77%
166,689 $776,000
Q2 2023

Aug 11, 2023

BUY
$4.62 - $7.54 $147,766 - $241,159
31,984 Added 22.36%
175,046 $936,000
Q1 2023

May 15, 2023

BUY
$4.82 - $7.24 $575,228 - $864,036
119,342 Added 503.13%
143,062 $1.03 Million
Q4 2022

Feb 13, 2023

BUY
$3.34 - $6.98 $79,224 - $165,565
23,720 New
23,720 $159,000
Q2 2022

Aug 11, 2022

SELL
$2.25 - $9.99 $85,549 - $379,839
-38,022 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$8.12 - $16.9 $129,213 - $268,929
15,913 Added 71.98%
38,022 $335,000
Q4 2021

Feb 14, 2022

BUY
$15.91 - $21.88 $351,754 - $483,744
22,109 New
22,109 $355,000
Q4 2020

Feb 11, 2021

SELL
$19.41 - $26.0 $366,208 - $490,542
-18,867 Closed
0 $0
Q3 2020

Nov 06, 2020

SELL
$24.69 - $31.6 $314,007 - $401,888
-12,718 Reduced 40.27%
18,867 $475,000
Q2 2020

Aug 07, 2020

BUY
$5.2 - $29.12 $164,242 - $919,755
31,585 New
31,585 $882,000
Q1 2020

May 08, 2020

SELL
$4.28 - $12.11 $59,209 - $167,529
-13,834 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$7.95 - $12.27 $109,980 - $169,743
13,834 New
13,834 $151,000
Q2 2019

Aug 09, 2019

SELL
$14.51 - $19.71 $474,085 - $643,984
-32,673 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$11.11 - $25.6 $362,997 - $836,428
32,673 New
32,673 $587,000
Q2 2018

Aug 07, 2018

SELL
$19.78 - $24.67 $806,549 - $1.01 Million
-40,776 Closed
0 $0
Q1 2018

May 03, 2018

BUY
$18.89 - $32.46 $770,258 - $1.32 Million
40,776 New
40,776 $1.03 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $186M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.